Application and Significance of FGF18 Detection by ELISA

As a main quantitative detection technology for FGF18, ELISA has become a pivotal detection method throughout the entire chain of FGF18 research from basic science to clinical translation, thanks to its technical advantages including accurate quantification, high throughput, easy operation, low cost, and a sensitivity level of picogram per milliliter (pg/mL). Its core value lies in providing objective and reproducible data on FGF18 expression and concentration for various research and application scenarios, thus supporting key work such as mechanism verification, disease assessment, and drug research and development (R&D). Its specific applications and corresponding significance are as follows: 

1. Basic Scientific Research

Application: Quantify the FGF18 content in biological samples including cell culture supernatant, animal tissue homogenate, and biological fluids such as serum, synovial fluid, and cerebrospinal fluid; analyze the expression patterns, spatiotemporal distribution, and regulatory changes of FGF18 in physiological and pathological processes such as skeletal development, cartilage homeostasis, tissue repair, and inflammatory response.
Significance: Verify the biological functions and action mechanisms of FGF18, clarify its core role in the occurrence and development of diseases, and provide fundamental experimental evidence for identifying FGF18 as a subsequent disease target or biomarker. This constitutes the prerequisite for conducting follow-up research. 

2. Clinical Research and Diagnosis

Application: Detect the FGF18 concentration in clinical samples (e.g., serum, synovial fluid, ascites) from patients with diseases such as osteoarthritis, ovarian cancer, and hepatocellular carcinoma; compare the expression differences of FGF18 between healthy populations and patients, and analyze its correlation with disease stage, severity, and recurrence risk.
Significance: On the one hand, develop FGF18 as an auxiliary diagnostic biomarker for diseases, providing a new detection index for the early screening of diseases. On the other hand, establish FGF18 as a prognostic indicator (e.g., high FGF18 expression in ovarian cancer indicates poor prognosis), which offers objective data support for clinicians to formulate personalized diagnosis and treatment plans and evaluate patient prognosis.

3. Drug R&D and Efficacy Monitoring

Application: In the R&D and clinical trials of FGF18-related targeted drugs (e.g., the cartilage repair drug Sprifermin), quantify the changes in in vivo FGF18 concentration after drug administration, and simultaneously monitor the FGF18 expression level in lesions and biological fluids of patients during the treatment process.
Significance: 
a. Evaluate the in vivo exposure, duration of action, and dosage efficacy of drugs, providing critical data for drug dosage optimization and the formulation of administration regimens.
b. Monitor the changes in FGF18 expression after treatment to directly reflect the regulatory effect of drugs on the target, objectively judge clinical efficacy, and meanwhile provide core clinical trial data for drug marketing authorization. 

4. Technical Advantages

ELISA addresses the shortcomings of traditional detection methods (e.g., Western Blot) for FGF18, such as poor quantitativeness, low throughput, and inability to implement large-scale sample testing. It enables batch screening of FGF18 samples, greatly improving research efficiency and reducing detection costs. As a key technical support for promoting the translation of FGF18 basic scientific research achievements into clinical diagnosis and drug application, ELISA makes the clinical implementation of FGF18 possible.